One of Nation's First Transplant Pharmacotherapy Team. Serving Transplant Recipients and Their Families since 1970s. Changing Lives. Striving for Excellence!
Joined June 2022
- Tweets 1,215
- Following 467
- Followers 294
- Likes 2,903
Photos and videos
UIC Transplant Pharmacotherapy Team retweeted
Important editorial published in AJT regarding the current requirement for insulin dependency for Pancreas transplant candidacy, particularly for patients with type 2 diabetes. @IU_Surgery @IPITAgroup @IPITA_YIC @AST_KPCOP
sciencedirect.com/science/ar…
2
4
149
UIC Transplant Pharmacotherapy Team retweeted
The RNA helicase DDX6 promotes immunosuppression in #cancer by repressing ADAR1-mediated #dsRNA stabilization, preventing interferon activation. Learn more in Science #Immunology: scim.ag/4eeZDga
2
11
37
2,604
UIC Transplant Pharmacotherapy Team retweeted
Jun 10
Is There a Role for Pentoxifylline in Diabetic Kidney Disease?
bit.ly/4rSpkru (FREE)
@AgarwalRajivMD
ALT Mechanism proposed to explain the anti-inflammatory effects of pentoxifylline. Inhibition of PDE by pentoxifylline increases cAMP levels, thus activating PKA. Active PKA inhibits ubiquitination that drives IkB to proteasome degradation thus preventing p50/p65 translocation and the expression of inflammatory cytokines and other genes. S
13
20
1,261
Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. Full study results: nej.md/4dXZ3od
Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation nej.md/4e1EZ4s
ALT Bar graph from an article published in the New England Journal of Medicine article showing interleukin-10 as measured by neutralization in interleukin-10 reporter assay and ELISA. The graph compares two groups: "Total Control" with a value of 0% and "Total IBD Cohorts" at 3.5% with a confidence interval of 3.0–4.1. Statistical notation shows P<0.001.
4
66
163
50,107
UIC Transplant Pharmacotherapy Team retweeted
We’re proud to share that Dr. Stephanie Dwyer Kaluzna was recently featured in Pharmacy Times! She discussed the latest advances in anticoagulation therapy for patients with atrial fibrillation.
ow.ly/yp9I50ZaFON
ALT Young woman with long straight brown hair wearing a white top and maroon jacket against a white background inside a red circular frame.
1
2
38
UIC Transplant Pharmacotherapy Team retweeted
Jun 7
🧬 Obexelimab: A New Way to Control B Cells
Unlike rituximab, which removes B cells, obexelimab functionally silences them by co-engaging CD19 and the inhibitory receptor FcγRIIB (CD32B).
🔹 Inhibits B-cell activation
🔹 Reduces plasmablast formation
🔹 Decreases antibody production
🔹 Suppresses inflammatory cytokines
🔹 Minimal B-cell depletion
Obexelimab turns B cells “OFF” rather than wiping them out, potentially preserving immune function while controlling autoimmune disease.
#RheumattDoc #MedTwitter #RheumTwitter #Medicine #rheumatology @docakx @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1
32
71
4,676
UIC Transplant Pharmacotherapy Team retweeted
Jun 8
SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art
doi.org/10.1093/ckj/sfaf350
59
137
4,695
UIC Transplant Pharmacotherapy Team retweeted
Redefining early allograft dysfunction in living donor liver transplantation: Towards adaptive, graft-specific, and AI-enabled models
journals.lww.com/lt/citation…
2
5
576
UIC Transplant Pharmacotherapy Team retweeted
Waitlist mortality in liver transplantation: Understanding metrics, regulatory implications, and clinical management strategies
journals.lww.com/lt/abstract…
5
6
5,138
UIC Transplant Pharmacotherapy Team retweeted
Major adverse cardiovascular events after liver transplantation: A call for a shared definition
journals.lww.com/lt/abstract…
6
15
991
UIC Transplant Pharmacotherapy Team retweeted
Physiological responses to the six-minute walk test in frail/pre-frail patients with cirrhosis awaiting transplantation
journals.lww.com/lt/abstract…
2
11
623
UIC Transplant Pharmacotherapy Team retweeted
May 12
Chloride at the spotlight—but not alone: toward a multi-ionic diuretic strategy
doi.org/10.1093/ckj/sfag119
16
39
2,181
UIC Transplant Pharmacotherapy Team retweeted
May 12
Recently, extracorporeal organ support (ECOS) or multiple organ support therapy (MOST) have emerged to address the need for strategies in patients with multiorgan failure. Read about these recent developments in #ASNKidneyNews: kidney.pub/KN1805-15
2
8
792
UIC Transplant Pharmacotherapy Team retweeted
This paper shows that, despite better early outcomes, progress has plateaued in the last 50 years of kidney transplant data. Long-term graft survival is declining in the modern era due to older, more comorbid recipients and rising infection-related deaths. tinyurl.com/2p9ucusb
5
11
1,017
UIC Transplant Pharmacotherapy Team retweeted
May 7
Oral versus injectable GLP-1 receptor agonists in clinical practice!
🆓doi.org/10.1093/ndt/gfag101
📸Comparison of advantages of oral versus injectable glucagon like peptide 1 receptor agonists
2
21
55
2,741
UIC Transplant Pharmacotherapy Team retweeted
#TBT to this week's featured top downloaded paper from 2025: Pregnancy After Solid Organ Transplantation: Review of the Evidence and Recommendations #Transplantation #Med tinyurl.com/5ae3a2f4
10
21
1,172
UIC Transplant Pharmacotherapy Team retweeted
Graft survival after liver transplantation using portable normothermic machine perfusion at a US center
journals.lww.com/lt/abstract…
2
6
499
UIC Transplant Pharmacotherapy Team retweeted
May 6
Associate Editor Amy Mottl will be presenting Highlights from AJKD tomorrow at #NKFClinicals!
Attend the Hot Topics in Nephrology Literature lunch workshop in Room 356-357 on Thursday, May 7, 11.30AM-1.30PM.
@NKF_NephPros
2
5
617
UIC Transplant Pharmacotherapy Team retweeted
A new Focus article discusses the role that Foxp3 plays in establishing regulatory T cell identity and highlights the therapeutic potential of engineered #Treg cells for #autoimmune disorders. @R_Stadhouders @mieke65124955 scim.ag/4cHVthh
26
97
5,800
Channing J. Der, PhD, and Jen Jen Yeh, MD, describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas.
Learn about the science behind the study in the editorial “Advances in RAS Therapeutics for Pancreatic Cancer,” from the University of North Carolina at Chapel Hill (@unc): nej.md/4neOTCE
ALT Science behind the Study Advances in RAS Therapeutics for Pancreatic Cancer Figure 1. Daraxonrasib Mechanism of Action and Resistance Mechanisms.
2
95
240
31,951